Korean J Med.
2024 Aug;99(4):180-188. 10.3904/kjm.2024.99.4.180.
What is Different about Recombinant Herpes Zoster Vaccine?
- Affiliations
-
- 1Department of Infectious Diseases, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, Korea
- KMID: 2558342
- DOI: http://doi.org/10.3904/kjm.2024.99.4.180
Abstract
- Herpes zoster (HZ) affects about one in three persons in their life time. Compared with the general population, older adults with immune senescence and individuals who are immunocompromised therapy are at increased risk for HZ, and its debilitating complications. To prevent HZ, two HZ vaccines, zoster vaccine live (ZVL) and recombinant zoster vaccine (RZV) are available. RZV is The Korean Society of Infectious Diseases revised guidelines for HZ vaccine in 2023, and recommended to vaccinate with RZV for adults ≥ aged 50 years and for severely immunocompromised adults aged ≥ 18 years. RZV is more effective for prevention of HZ than ZVL. RZV is nonreplicating and is thus safe in immunocompromised patients. RZV has clinically acceptable safety profile. This review will help clinicians update knowledge about RZV and identify eligible subjects who may benefit from HZ vaccinations.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Herpes zoster vaccine in Korea
- Two Cases of Herpes Zoster in healthy Children after Varicella Vaccination
- Update in varicella vaccination
- Herpes zoster ophthalmicus after COVID-19 vaccine booster in healthy younger adult: a case report
- Recombinant zoster vaccine (Shingrix®): a new option for the prevention of herpes zoster and postherpetic neuralgia
